- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01514825
A Study to Investigate the Plasma Concentration of YM150 After Repeated Administration to Elderly Subjects
January 23, 2012 updated by: Astellas Pharma Inc
YM150 Clinical Pharmacology Study - Repeated Oral Administration to Elderly Subjects
The purpose of this study is to evaluate the safety and plasma concentration change of YM150 after repeated administration to healthy elderly male and female subjects.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
36
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Kyushu, Japan
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
65 years to 79 years (OLDER_ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Healthy, as judged by the investigator or sub-investigator based on the results of physical examinations and all tests
- Body weight: male: ≥45.0 kg, <85.0 kg; female: ≥40.0 kg, <75.0 kg
- BMI (at screening): ≥17.6, <30.0
Exclusion Criteria:
- Use of any other investigational drug in another clinical study or a post-marketing clinical study within 120 days before the administration of the study drug
- Donated 400 mL of whole blood within 90 days, 200 mL of whole blood within 30 days, or blood components within 14 days before the screening assessment.
- Any surgical intervention (including tooth extraction) or trauma within 90 days before hospitalization until the administration, or plan of any surgical intervention within 10 week after the final administration
- A deviation from the normal reference range of blood pressure, pulse rate, body temperature, or 12-lead ECG
- PT or aPTT on blood coagulation tests outside the upper or lower reference limits (PT: 9.9 to 15.4 sec.; aPTT: 22.5 to 49.5 sec.)
- Upper gastrointestinal disease (e.g. nausea, vomiting, stomachache) within 7 days before the study
- Concurrent or previous hepatic disease (e.g. viral hepatitis, drug-induced liver injury)
- Concurrent or previous heart disease (e.g. congestive heart failure, angina pectoris, arrhythmia requiring treatment)
- Concurrent or previous respiratory disease (e.g. serious bronchial asthma, chronic bronchitis; except for a history of childhood asthma)
- Concurrent or previous renal disease (e.g. acute renal failure, glomerulonephritis, interstitial nephritis; except for a history of calculus)
- Concurrent or previous malignant tumor
- Excessive smoking or drinking habit [measure of "excessive": alcohol: average 45 g/day (a 633 mL bottle of beer contains 25 g of alcohol, and 180 mL of Japanese sake contains 22 g of alcohol), smoking: average 20 cigarettes/day]
- Previous treatment with YM150
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
PLACEBO_COMPARATOR: placebo group
|
oral
|
EXPERIMENTAL: YM150 low dose group
|
oral
Other Names:
|
EXPERIMENTAL: YM150 middle dose group
|
oral
Other Names:
|
EXPERIMENTAL: YM150 high dose group
|
oral
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Cmax of YM150 assessed by its plasma concentration change
Time Frame: for 7 days
|
for 7 days
|
AUC of YM150 assessed by its plasma concentration change
Time Frame: for 7 days
|
for 7 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Changes in the blood coaggregation indexes such as PT(INR), aPTT and FXa
Time Frame: for 7 days
|
for 7 days
|
Safety assessed by the incidence of adverse events, vital signs, 12-lead ECG and labo-tests
Time Frame: for 7 days
|
for 7 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2006
Primary Completion (ACTUAL)
February 1, 2007
Study Completion (ACTUAL)
February 1, 2007
Study Registration Dates
First Submitted
January 18, 2012
First Submitted That Met QC Criteria
January 20, 2012
First Posted (ESTIMATE)
January 23, 2012
Study Record Updates
Last Update Posted (ESTIMATE)
January 24, 2012
Last Update Submitted That Met QC Criteria
January 23, 2012
Last Verified
January 1, 2012
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 150-CL-026
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Elderly Subject
-
Centre Hospitalier Régional Metz-ThionvilleCompleted
-
Changchun GeneScience Pharmaceutical Co., Ltd.Completed
-
CelltrionCompletedHealthy SubjectKorea, Republic of
-
Ohio State University Comprehensive Cancer CenterNational Cancer Institute (NCI)Active, not recruiting
-
Staidson (Beijing) Biopharmaceuticals Co., LtdCompleted
-
GeneScience Pharmaceuticals Co., Ltd.Completed
-
Kyowa Kirin Co., Ltd.Completed
-
Ohio State University Comprehensive Cancer CenterActive, not recruitingHealthy SubjectUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI); Texas A&M UniversityCompletedHealthy SubjectUnited States
-
Whanin Pharmaceutical CompanyCompletedHealthy SubjectKorea, Republic of
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States